Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

CNGB1 and Allied Disorders

Study of CNGB1 Retinitis Pigmentosa and Allied Hereditary Disorders

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Mutations in the rod-expressed gene, cyclic nucleotide-gated channel beta subunit (CNGB1) and associated inborn errors in metabolism are causes of retinal disease that causes progressive loss of vision. Retinitis pigmentosa (RP) is a major cause of untreatable blindness associated with CNGB1 (CNGB1-RP). RP involves the death of photoreceptor cells that can be caused by mutations in a number of different genes. Treatment by gene therapy could prevent blindness in cases of inherited retinal dystrophies including RP. In the future RP due to mutations in CNGB1 may be treatable by gene therapy since this form of photoreceptor degeneration involves a slow loss of rod photoreceptor cells. This provides a wide window of opportunity for the identification of patients and initiation of treatment. Our efforts are directed toward developing gene therapy as a treatment. To this end, our objective is to better understand the disease process of CNGB1-RP and other allied inherited disorders so that we can develop clinical tests to measure the outcomes of treatment.

Who May Be Eligible (Plain English)

Who May Qualify: - Diagnosis of CNGB1-associated RP by study physician, who are trained retinal specialists in the university clinic - Must be able to commit to 4 follow-up study visits (3 years) Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Diagnosis of CNGB1-associated RP by study physician, who are trained retinal specialists in the university clinic * Must be able to commit to 4 follow-up study visits (3 years)

Treatments Being Tested

OTHER

No intervention, this is a natural history progression study

The objective is to better understand the disease process of CNGB1-RP so that we can develop clinical tests to measure the outcomes of treatment.

Locations (6)

Dr. Stephen H. Tsang
New York, New York, United States
Wills Eye Hospital
Philadelphia, Pennsylvania, United States
Institut de la Vision/Centre de maladies rares du Centre Hospitalier National Ophtalmologique des Quinze-Vingts
Paris, France
Klinikum der Universität München University Eye Hospital, Ludwig-Maximilians-University (LMU) Munich
München, Bavaria, Germany
Eberhard Karls University Tubingen
Tübingen, Germany
Moorfields Eye Hospital NHS Foundation Trust
London, United Kingdom